uridine triacetate (PN 401)

News alerts, weekly reports and conference planners

Company:

Wellstat

Drug class:

ATP stimulant, Mitochondrial protein stimulant

‹

›

1year

Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing. (PubMed, Cancer Chemother Pharmacol)

It is our recommendation to perform DPD deficiency in curative intent cancer treatment and this information can increasingly be obtained in standard tumor NGS profiling, a growing norm in medical oncology.

1 year ago

Journal

DPYD (Dihydropyrimidine Dehydrogenase)

5-fluorouracil • capecitabine • uridine triacetate (PN 401)

over5years

Capecitabine-induced cerebellar toxicity and TYMS pharmacogenetics. (PubMed, Anticancer Drugs)

No re-challenge was given to this patient but he was able to tolerate irinotecan, oxaliplatin, and bevacizumab without any toxicities. Patients on fluoropyrimidines, including capecitabine with new neurological symptoms must be investigated for a rare but real central neurotoxicity. Though the treatment of 5-FU neurotoxicity is supportive care but use of uridine triacetate may be indicated in few patients, especially with overdose.

over 5 years ago

Journal

TYMS (Thymidylate Synthetase)

Avastin (bevacizumab) • capecitabine • oxaliplatin • irinotecan • fluorouracil topical • uridine triacetate (PN 401)